ArticleCureus2026
Unveiling Antibiotic Resistance in Ventilator-Associated Pneumonia Patients: A Comprehensive Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentilator-associated pneumonia (VAP) remains a major healthcare-associated infection, especially in resource-limited settings where multidrug-resistant organisms are prevalent. This study assessed the bacteriological profile and antimicrobial susceptibility patterns of endotracheal aspirates (ETA) from clinically suspected VAP patients in a tertiary care ICU, and compared microbial distribution between early and late-onset VAP.
methodsA descriptive cross-sectional study was conducted from October 2024 to September 2025 in a tertiary care teaching hospital. Adult patients who were mechanically ventilated for more than 48 hours and met the modified Clinical Pulmonary Infection Score (CPIS) criteria (score >6) were included. ETAs were analyzed using semi-quantitative culture methods, with ≥10⁵ CFU/mL considered significant, and antimicrobial susceptibility testing was performed in accordance with CLSI 2023 guidelines. Demographic variables, risk factors, bacterial isolates, and resistance patterns were analysed using chi-square tests.
resultsAmong 596 ventilated patients, 195 (incidence proportion 32.7%) had significant culture-positive VAP. The incidence density was 33.6 per 1000 ventilator-days. Early-onset VAP accounted for 57.9% (113/195) and late-onset VAP for 42.1% (82/195). No significant association was observed between VAP onset and age, sex, or indication for intubation. Gram-negative pathogens predominated in both groups (76.1% early vs. 78% late).
conclusionVAP burden in this ICU remains high, with Gram-negative multidrug-resistant organisms, particularly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.